Crossmark

First-in-class HIF-2α therapy in genitourinary oncology: Belzutifan from von Hippel–Lindau disease to advanced renal cell carcinoma

Published Online: 2026-01-21

Authors

Karaman, Irem

Erdem, Dilek

Cetin, Bulent https://orcid.org/0000-0001-8628-0864
License Information

Text and Data Mining valid from 2026-01-21

Version of Record valid from 2026-01-21
More Information

Article History

Received: 26 August 2025

Accepted: 18 December 2025

First Online: 21 January 2026

Declarations

:

: The authors declare no competing interests.

: Not applicable.

Document is current